The Centers for Disease Control and Prevention (CDC) has released its 2026 Antimicrobial Resistance Threats Report, identifying 19 bacterial and fungal pathogens as urgent, serious, or concerning threats to public health. The report estimates that drug-resistant germs cause an average of 9.7 million infections and 50,800 deaths in the U.S. each year, marking a significant increase from prior CDC data.
The CDC’s latest figures represent a sharp rise in infections compared to its 2019 report, which recorded approximately 2.8 million cases and 35,000 deaths annually. The agency did not provide a yearly breakdown of cases or deaths in the 2026 update.
CDC Identifies Four 'Urgent' Threats
The report categorizes pathogens by threat level, with four labeled as 'urgent', the highest classification. These include:
- Candida auris (C. auris): A drug-resistant fungus that has spread rapidly in healthcare settings. The CDC reports a nearly five-fold increase in clinical cases between 2019 and 2022, with 6,700 infections documented in the U.S. in 2024 alone. The fungus can survive on surfaces for weeks and has been detected in at least 27 states this year.
- Acinetobacter: A bacterium often associated with hospital-acquired infections, particularly in intensive care units.
- Enterobacterales: A family of bacteria that includes strains resistant to multiple antibiotics.
- Neisseria gonorrhoeae: The bacterium responsible for gonorrhea, which has developed resistance to several treatments.
MRSA: A Persistent 'Serious Threat'
The CDC classifies methicillin-resistant Staphylococcus aureus (MRSA) as a 'serious threat', estimating 220,997 cases and 7,499 deaths among hospitalized patients in 2023, with healthcare costs exceeding $1.55 billion. MRSA infections often occur in hospitals, where it accounts for 40 to 50% of staph infections. The bacteria can enter the body through wounds or medical devices, leading to severe complications such as pneumonia, bloodstream infections, and sepsis.
Healthcare and Economic Impact
The CDC warns that drug-resistant infections prolong hospital stays, increase healthcare costs, and complicate treatments for serious conditions like cancer chemotherapy, organ transplants, and surgeries. The agency estimates that these infections drive nearly $12 billion in healthcare costs annually in the U.S.
Expert and Public Health Response
Infectious disease specialists have expressed concern over the rising threat. Dr. Wendy Armstrong, president of the Infectious Diseases Society of America, stated in a response to the report that the statistics reflect real patient experiences, including prolonged hospitalizations and increased mortality risks. She emphasized that the spread of these pathogens undermines critical medical procedures and increases the difficulty of patient care.
The CDC’s projections suggest the situation may worsen, with researchers estimating 317,000 annual deaths from superbugs in North America by 2050 if current trends continue.
Pathogen Spread and Risk Factors
Many of the most dangerous pathogens thrive in healthcare settings, including hospitals and long-term care facilities. Factors contributing to their spread include:
- Contaminated surfaces and medical equipment: Some pathogens, like C. auris, can survive on surfaces for extended periods.
- Patient vulnerability: Individuals with weakened immune systems, chronic illnesses, or those undergoing invasive medical procedures are at higher risk.
- Antibiotic overuse: The development of resistance is accelerated by the overprescription and misuse of antibiotics in both human and agricultural settings.
The CDC continues to monitor these threats and urges enhanced infection control measures, including improved hygiene protocols, judicious antibiotic use, and rapid diagnostic testing to curb the spread of drug-resistant germs.